T1	Participants 2778 2918	CONCLUSIONS AND RELEVANCE Ocriplasmin produces clinically meaningful improvement in patient-reported visual function in symptomatic VMA/VMT.
T2	Participants 1660 1749	RESULTS Across the 2 studies, 464 patients received ocriplasmin and 188 received placebo.
T3	Participants 412 654	OBJECTIVE To determine the impact of intravitreal ocriplasmin on patient-reported visual function using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) during a 6-month follow-up in patients with symptomatic VMA.
T4	Participants 0 214	Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
T5	Participants 918 1046	A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 Î¼m or smaller, were studied.
